Loading...
XNYSSYK
Market cap138bUSD
Dec 20, Last price  
364.60USD
1D
2.09%
1Q
-0.06%
Jan 2017
204.32%
Name

Stryker Corp

Chart & Performance

D1W1MN
XNYS:SYK chart
P/E
43.92
P/S
6.78
EPS
8.30
Div Yield, %
0.82%
Shrs. gr., 5y
0.18%
Rev. gr., 5y
8.55%
Revenues
20.50b
+11.11%
4,262,300,0004,871,500,0005,405,600,0006,000,500,0006,718,200,0006,723,100,0007,320,000,0008,307,000,0008,657,000,0009,021,000,0009,675,000,0009,946,000,00011,325,000,00012,444,000,00013,601,000,00014,884,000,00014,351,000,00017,108,000,00018,449,000,00020,498,000,000
Net income
3.17b
+34.22%
465,700,000675,200,000777,700,0001,017,400,0001,147,800,0001,107,400,0001,273,400,0001,345,000,0001,298,000,0001,006,000,000515,000,0001,439,000,0001,647,000,0001,020,000,0003,553,000,0002,083,000,0001,599,000,0001,994,000,0002,358,000,0003,165,000,000
CFO
3.71b
+41.43%
593,300,000863,800,000867,300,0001,028,300,0001,175,900,0001,460,700,0001,547,400,0001,434,000,0001,657,000,0001,886,000,0001,782,000,000899,000,0001,812,000,0001,559,000,0002,610,000,0002,191,000,0003,277,000,0003,263,000,0002,624,000,0003,711,000,000
Dividend
Sep 30, 20240.8 USD/sh
Earnings
Jan 28, 2025

Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
URL
https://www.stryker.com/
IPO date
Mar 17, 1980
Employees
51,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
20,498,000
11.11%
18,449,000
7.84%
17,108,000
19.21%
Cost of revenue
8,789,000
8,325,000
7,375,000
Unusual Expense (Income)
NOPBT
11,709,000
10,124,000
9,733,000
NOPBT Margin
57.12%
54.88%
56.89%
Operating Taxes
508,000
325,000
287,000
Tax Rate
4.34%
3.21%
2.95%
NOPAT
11,201,000
9,799,000
9,446,000
Net income
3,165,000
34.22%
2,358,000
18.25%
1,994,000
24.70%
Dividends
(1,139,000)
(1,051,000)
(950,000)
Dividend yield
0.99%
1.12%
0.93%
Proceeds from repurchase of equity
(155,000)
BB yield
0.13%
Debt
Debt current
2,237,000
1,191,000
7,000
Long-term debt
11,613,000
12,214,000
12,782,000
Deferred revenue
(67,000)
(68,000)
Other long-term liabilities
2,141,000
2,108,000
2,733,000
Net debt
10,797,000
11,387,000
9,704,000
Cash flow
Cash from operating activities
3,711,000
2,624,000
3,263,000
CAPEX
(575,000)
(588,000)
(525,000)
Cash from investing activities
(962,000)
(2,924,000)
(859,000)
Cash from financing activities
(1,594,000)
(749,000)
(2,365,000)
FCF
10,019,000
8,883,000
9,312,000
Balance
Cash
3,053,000
1,928,000
3,019,000
Long term investments
90,000
66,000
Excess cash
2,028,100
1,095,550
2,229,600
Stockholders' equity
16,393,000
14,582,000
12,987,000
Invested Capital
32,199,900
30,317,450
27,599,400
ROIC
35.83%
33.84%
34.34%
ROCE
34.21%
32.16%
32.56%
EV
Common stock shares outstanding
383,700
382,200
382,300
Price
299.46
22.48%
244.49
-8.57%
267.42
9.13%
Market cap
114,902,802
22.96%
93,444,078
-8.60%
102,234,666
9.71%
EV
125,699,802
104,831,078
111,938,666
EBITDA
12,737,000
11,122,000
10,723,000
EV/EBITDA
9.87
9.43
10.44
Interest
356,000
158,000
337,000
Interest/NOPBT
3.04%
1.56%
3.46%